Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-17T16:39:58.021Z Has data issue: false hasContentIssue false

Chapter 14 - Blastic Plasmacytoid Dendritic Cell Neoplasm

from Section IV - Precursor Hematopoietic Neoplasms and Related Neoplasms

Published online by Cambridge University Press:  25 November 2023

By
Stephanie D. Schniederjan ,
Aurelia Meloni-Ehrig ,
Caroline An  and
Kristian T. Schafernak
Edited by
Silvia Tse Bunting ,
Xiayuan Liang ,
Michele E. Paessler  and
Satheesh Chonat
Silvia Tse Bunting
Affiliation:
Cleveland Clinic Florida Weston
Xiayuan Liang
Affiliation:
University of Colorado
Michele E. Paessler
Affiliation:
University of Pennsylvania School of Medicine
Satheesh Chonat
Affiliation:
Emory University, Atlanta
Get access

Summary

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive malignancy that is notable for frequently presenting with skin lesions and for its unfavorable prognosis. The revised fourth edition of the World Health Organization classification places BPDCN in a separate, stand-alone chapter between acute myeloid leukemia and acute leukemias of ambiguous lineage in recognition of its distinct lineage and aggressive clinical behavior. [1]. Knowledge of the cell of origin and the increasing availability of markers specific for plasmacytoid dendritic cells has recently allowed the recognition of heterogeneity in the clinical presentation and immunophenotype of BPDCN [2].

Type
Chapter
Information
Atlas of Pediatric Hematopathology , pp. 140 - 146
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Facchetti, FP, Petrella, T, Pileri, SA. Blastic plasmacytoid dendritic cell neoplasm. In Swerdlow, SH, Campo, E, Harris, NL, Jaffe, ES, Pileri, SA, Stein, H, et al. eds. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed., revised ed. Lyon: International Agency for Research on Cancer; 2017:174–7.Google Scholar
Martín-Martín, LLA, Vidriales, B, Caballero, MD, Rodrigues, AS, Ferreira, SI, Lima, M, et al. Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile. Oncotarget. 2015; 6(22): 19204–16.CrossRefGoogle ScholarPubMed
Gurbaxani, S. Blastic plasmacytoid dendritic cell neoplasm. In Larson, RA, ed. UpToDate. Waltham, MA: Wolters Kluwer; 2019.Google Scholar
Jegalian, AG, Buxbaum, NP, Facchetti, F, Raffeld, M, Pittaluga, S, Wayne, AS, et al. Blastic plasmacytoid dendritic cell neoplasm in children: Diagnostic features and clinical implications. Haematologica. 2010; 95(11): 1873–9.CrossRefGoogle ScholarPubMed
Tzankov, A, Hebeda, K, Kremer, M, Leguit, R, Orazi, A, Van der Walt, J, et al. Plasmacytoid dendritic cell proliferations and neoplasms involving the bone marrow: Summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Group, Basel 2016. Ann Hematol. 2017; 96(5): 765–77.CrossRefGoogle Scholar
Bekkenk, MW, Jansen, PM, Meijer, CJLM, Willemze, R. CD56+ hematological neoplasms presenting in the skin: A retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol. 2004; 15(7): 1097–1108.CrossRefGoogle ScholarPubMed
Pagano, L, Valentini, CG, Pulsoni, A, Fisogni, S, Carluccio, P, Mannelli, F, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: An Italian multicenter study. Haematologica. 2013; 98(2): 239–46.CrossRefGoogle ScholarPubMed
Dijkman, R, Van Doorn, R, Szuhai, K, Willemze, R, Vermeer, MH, Tensen, CP. Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood. 2007; 109(4): 1720–7.CrossRefGoogle ScholarPubMed
Suzuki, Y, Kato, S, Kohno, K, Satou, A, Eladl, AE, Asano, N, et al. Clinicopathological analysis of 46 cases with CD4(+) and/or CD56(+) immature haematolymphoid malignancy: Reappraisal of blastic plasmacytoid dendritic cell and related neoplasms. Histopathology. 2017; 71(6): 972–84.CrossRefGoogle ScholarPubMed
Facchetti, F, Cigognetti, M, Fisogni, S, Rossi, G, Lonardi, S, Vermi, W. Neoplasms derived from plasmacytoid dendritic cells. Mod Pathol. 2016; 29(2): 98–111.CrossRefGoogle ScholarPubMed
Sukswai, N, Aung, PP, Yin, CC, Li, S, Wang, W, Wang, SA, et al. Dual expression of TCF4 and CD123 is highly sensitive and specific for blastic plasmacytoid dendritic cell neoplasm. Am J Surg Pathol. 2019; 43(10): 1429–37.CrossRefGoogle ScholarPubMed
Leroux, D, Mugneret, F, Callanan, M, Radford-Weiss, I, Dastugue, N, Feuillard, J, et al. CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: A study of 21 cases by the Groupe Francais de Cytogenetique Hematologique. Blood. 2002; 99(11): 4154–9.CrossRefGoogle ScholarPubMed
Lucioni, M, Novara, F, Fiandrino, G, Riboni, R, Fanoni, D, Arra, M, et al. Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: Focus on biallelic locus 9p21.3 deletion. Blood. 2011; 118(17): 4591–4.CrossRefGoogle ScholarPubMed
Menezes, J, Acquadro, F, Wiseman, M, Gomez-Lopez, G, Salgado, RN, Talavera-Casanas, JG, et al. Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2014; 28(4): 823–9.CrossRefGoogle ScholarPubMed
Taylor, J, Kim, SS, Stevenson, KE, Yoda, A, Kopp, N, Louissaint, A, et al. Loss-of-function mutations in the splicing factor ZRSR2 are common in blastic plasmacytoid dendritic cell neoplasm and have male predominance. Blood. 2013; 122(21): 741.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×